Olive AI Denied Claims Resurrection
One-Liner
Reviving Olive AI's denied claims appeal automation for healthcare providers, using a different business model.
Kill Reason
Denied claims appeal automation is a crowded space with 10+ funded competitors (Waystar, Experian Health, Change Healthcare/Optum, Infinx, Apixio, AKASA) and deep EHR integration moats. Olive failed from unfocused execution, not market absence.
What do you think?
Related ideas you can explore free:
killed: Existing pharmacy intelligence platforms (Bluesight, GPO tools from Vizient and Premier) already have the data infrastructure. Crisis-mode dashboard is a feature they add in days, not a new product. Crisis-driven urgency benefits incumbents.
killed: Pharmacies have zero incentive to share real-time stock data (benefits competitors). Crowdsourced pivot fails from frequency trap (individual patient searches rarely) and medication privacy concerns. Two-sided marketplace where one side won't participate.
killed: Hardware cost ($1M/pod) combined with annual screening frequency makes unit economics impossible, regardless of customer. Quest/Labcorp already serve corporate wellness efficiently at $35-75/person. The fundamental problem is hardware cost, not customer selection.